Integron-Associated DfrB4, a Previously Uncharacterized Member of the Trimethoprim-Resistant Dihydrofolate Reductase B Family, Is a Clinically Identified Emergent Source of Antibiotic Resistance

Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02665-16. doi: 10.1128/AAC.02665-16. Print 2017 May.

Abstract

Whole-genome sequencing of trimethoprim-resistant Escherichia coli clinical isolates identified a member of the trimethoprim-resistant type II dihydrofolate reductase gene family (dfrB). The dfrB4 gene was located within a class I integron flanked by multiple resistance genes. This arrangement was previously reported in a 130.6-kb multiresistance plasmid. The DfrB4 protein conferred a >2,000-fold increased trimethoprim resistance on overexpression in E. coli Our results are consistent with the finding that dfrB4 contributes to clinical trimethoprim resistance.

Keywords: E. coli clinical isolates; antibiotic-resistant genes; class I integron; dfrB4; trimethoprim resistance; type II dihydrofolate reductase; urinary tract infection.

MeSH terms

  • Anti-Infective Agents, Urinary / pharmacology*
  • Drug Resistance, Bacterial / genetics
  • Escherichia coli / drug effects
  • Escherichia coli / genetics*
  • Escherichia coli / isolation & purification
  • Escherichia coli Proteins / genetics*
  • Humans
  • Integrons / genetics*
  • Microbial Sensitivity Tests
  • Tetrahydrofolate Dehydrogenase / genetics*
  • Trimethoprim / pharmacology*
  • Trimethoprim Resistance / genetics*
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / microbiology

Substances

  • Anti-Infective Agents, Urinary
  • DfrB4 protein, E coli
  • Escherichia coli Proteins
  • Trimethoprim
  • dihydrofolate reductase type II
  • Tetrahydrofolate Dehydrogenase

Grants and funding